Crenolanib-Based Solutions for Niche Markets and Extreme Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept adapts crenolanib-based treatments for FLT3 mutated proliferative disorders to address specific, narrow market needs and unique operational environments, such as disaster relief, extreme weather conditions, high-security settings, and areas with limited access to medical resources.
Background and Problem Solved
The original patent disclosed crenolanib-based treatments for FLT3 mutated proliferative disorders, but these treatments may not be suitable for niche markets or extreme environments. This inventive concept addresses the limitations of the original patent by providing specialized solutions for these specific contexts.
Detailed Description of the Inventive Concept
The inventive concept comprises four main areas of innovation: (1) a system for treating hematological malignancies in remote disaster relief areas, featuring a crenolanib-based pharmaceutical composition and a portable, solar-powered refrigeration unit; (2) a method for treating FLT3 mutated proliferative disorders in extreme weather conditions, utilizing a wind-resistant, waterproof shelter for administration; (3) a high-security, tamper-evident container for storing and transporting crenolanib-based pharmaceutical compositions in high-security environments; and (4) a method for treating hematological malignancies in areas with limited access to medical resources, leveraging a telemedicine platform for remote monitoring and consultation. Additionally, a portable, battery-powered diagnostic device for detecting FLT3 mutations in subjects suffering from hematological malignancies in disaster relief areas is disclosed.
Novelty and Inventive Step
The inventive concept's novelty lies in its adaptation of crenolanib-based treatments to specific, narrow market needs and unique operational environments, which is non-obvious compared to the original patent. The inventive step is the combination of crenolanib-based pharmaceutical compositions with specialized equipment, infrastructure, and logistical solutions tailored to these niche contexts.
Alternative Embodiments and Variations
Alternative embodiments may include modifications to the portable refrigeration unit, wind-resistant shelter, or high-security container to accommodate different environmental conditions or security requirements. Variations may also involve integrating the crenolanib-based treatment with other diagnostic tools or telemedicine platforms to enhance patient care.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in niche markets, such as disaster relief, extreme weather conditions, high-security settings, and areas with limited access to medical resources. Target industries include pharmaceutical companies, medical device manufacturers, and telemedicine service providers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical oncology, specifically targeted cancer therapeutics for hematological malignancies with a focus on tyrosine kinase inhibitors and personalized treatment strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmacology or oncology, experienced in developing targeted cancer treatments, familiar with drug delivery systems, diagnostic technologies, and adaptive medical solutions for challenging environments
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core technology by applying standard engineering problem-solving techniques to expand crenolanib's treatment applicability across challenging medical contexts. The disclosed adaptations leverage known pharmaceutical and medical engineering principles to address specific environmental and logistical challenges. These variations represent incremental improvements that would be obvious to a skilled practitioner seeking to expand the utility of an existing targeted cancer treatment approach.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,546 |
|---|---|
| Title | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment |
| Assignee(s) | Arog Pharmaceuticals, Inc. |